

September 24, 2013



Navidea Biopharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference

– CEO to Provide Business and Development Program Updates –

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAV), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, Navidea Chief Executive Officer, will participate at BioCentury's NewsMakers in the Biotech Industry Conference on September 27, 2013 at the Millennium Broadway Hotel and Conference Center in New York City, NY. Dr. Pykett will provide an update of the Company and its development programs including initial data from its Manocept™ platform at 10:00 AM EDT.

Investors and the public are invited to listen to a live webcast of Dr. Pykett's presentation at <http://www.visualwebcaster.com/event.asp?id=95779>. Following the conference, the webcast will be archived for approximately 30 days.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek® (technetium 99m tilmanocept) Injection, NAV4694, NAV5001 and RIGScan™ – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's first commercial agent, Lymphoseek, was approved by the FDA in March 2013. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
or
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200

Source: Navidea Biopharmaceuticals, Inc.